CPSE:BAVABiotechs
Bavarian Nordic (CPSE:BAVA) Could Be 34% Undervalued Following VIMKUNYA Canada Approval
Health Canada has approved Bavarian Nordic (CPSE:BAVA)'s VIMKUNYA vaccine for chikungunya prevention in individuals 12 and older, marking its fifth major regulatory clearance across North America and Europe for travelers to affected regions.
See our latest analysis for Bavarian Nordic.
Bavarian Nordic's latest VIMKUNYA approval comes as the stock trades at DKK180.0, with a 7 day share price return of 4.35% but a year to date share price return that is down 6.64%. The 1 year total shareholder...